Cargando…

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

BACKGROUND: Mortality of patients with coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of pandemic outbreak, the number of patients can exceed maximum capacity of intensive care units (ICUs), and, thus, these individuals of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cavalli, Giulio, De Luca, Giacomo, Campochiaro, Corrado, Della-Torre, Emanuel, Ripa, Marco, Canetti, Diana, Oltolini, Chiara, Castiglioni, Barbara, Tassan Din, Chiara, Boffini, Nicola, Tomelleri, Alessandro, Farina, Nicola, Ruggeri, Annalisa, Rovere-Querini, Patrizia, Di Lucca, Giuseppe, Martinenghi, Sabina, Scotti, Raffaella, Tresoldi, Moreno, Ciceri, Fabio, Landoni, Giovanni, Zangrillo, Alberto, Scarpellini, Paolo, Dagna, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252085/ https://www.ncbi.nlm.nih.gov/pubmed/32501454 http://dx.doi.org/10.1016/S2665-9913(20)30127-2

Ejemplares similares

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
por: Cavalli, Giulio, et al.
Publicado: (2021)

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
por: De Luca, Giacomo, et al.
Publicado: (2020)

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
por: Della-Torre, Emanuel, et al.
Publicado: (2020)

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
por: Campochiaro, Corrado, et al.
Publicado: (2020)

Anakinra for patients with COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
por: Ripa, Marco, et al.
Publicado: (2021)

Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation: Life-threating Features Within the Early Post-engraftment Phase
por: Oltolini, Chiara, et al.
Publicado: (2020)

505. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2021)

Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2022)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19
por: Spagnuolo, V., et al.
Publicado: (2021)

Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19
por: Spagnuolo, V., et al.
Publicado: (2020)

High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19
por: Ripa, Marco, et al.
Publicado: (2022)

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis
por: Ciceri, Fabio, et al.
Publicado: (2023)

Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series
por: Clark, Kristina E N, et al.
Publicado: (2020)

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
por: Bozzi, Giorgio, et al.
Publicado: (2021)

Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.
por: Pasin, Laura, et al.
Publicado: (2021)

Frailty as a predictor of mortality in COVID-19 patients receiving CPAP for respiratory insufficiency
por: Damanti, Sarah, et al.
Publicado: (2022)

Adult-onset Still’s disease complicated by Guillain-Barré syndrome
por: Farina, Nicola, et al.
Publicado: (2023)

Initial chest radiographs and artificial intelligence (AI) predict clinical outcomes in COVID-19 patients: analysis of 697 Italian patients
por: Mushtaq, Junaid, et al.
Publicado: (2020)

Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids
por: Calò Carducci, Francesca I., et al.
Publicado: (2020)

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
por: Tomelleri, Alessandro, et al.
Publicado: (2018)

Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy
por: Ciceri, Fabio, et al.
Publicado: (2020)

One year later: The case of tocilizumab in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2022)

2408. Is Shorter Antibiotic Treatment Feasible in Patients with Cardiac Implantable Electronic Devices (CIED) Infections? Impact of Treatment Duration on 6-Month Recurrence and Mortality
por: Ponta, Giacomo, et al.
Publicado: (2023)

Effect of anakinra in COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
por: Cavalli, Giulio, et al.
Publicado: (2020)

Post-COVID-19 follow-up clinic: depicting chronicity of a new disease
por: Rovere-Querini, Patrizia, et al.
Publicado: (2020)

Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis
por: Tomelleri, Alessandro, et al.
Publicado: (2022)

Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency
por: Zangrillo, Alberto, et al.
Publicado: (2023)

Pulmonary Vascular Thrombosis in COVID-19 Pneumonia
por: De Cobelli, Francesco, et al.
Publicado: (2021)

Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey
por: Tomelleri, Alessandro, et al.
Publicado: (2020)

Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials
por: Belletti, Alessandro, et al.
Publicado: (2021)

Novel Coronavirus Disease (COVID-19) in Italian Patients: Gender Differences in Presentation and Severity
por: Baiardo Redaelli, Martina, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
por: Bonaventura, Aldo, et al.
Publicado: (2022)

Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study
por: De Lorenzo, Rebecca, et al.
Publicado: (2020)

Drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with COVID-19
por: Ramirez, Giuseppe A., et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment
por: Yurttutan, Sadık, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4s82aapl882l2p6chdjjgbf91v